Adaptive Biotechnologies Corp(ADPT)昨日盘中股价大涨8.77%,引发市场热议。此前该公司发布的2024年第三季度财报数据超出市场预期,成为引发股价大涨的主因。
数据显示,Adaptive Biotechnologies第三季度每股亏损22美分,好于分析师预期的29美分亏损;营收同比增长22.5%至4644万美元,也高于分析师预期的4021万美元。盈利与营收的双双超预期,显示该公司业务发展较为稳健。
公司主打产品clonoSEQ是获FDA授权用于检测和监测多发性骨髓瘤等多种淋巴癌的临床诊断产品。分析人士指出,财报数据表现符合公司在临床诊断市场扩张的预期,增强了投资者对该公司长期前景的信心,从而推动股价大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.